Clinical and Biomarker Effects of Depot Medroxyprogesterone Acetate in Females With Sickle Cell Disease

Inclusion Criteria

• •1. Provision of signed and dated informed consent form
• •2. Female, aged 18-50 years old
• •3. Diagnosis of sickle cell disease (SS, SB0,SB+,SC)
• •4. Report of at least 1 vaso-occlusive pain episode per month on average in the previous 6 months
• •5. At least 1 and no more than 10 medical presentations (e.g. hospitalization, emergencyroom visit, outpatient infusion visit) for vaso-occlusive pain during the past year, unless approved by study PI Andrea Roe
• •6. Willing to discontinue any hormonal contraception at the time of enrollment. Washout period of 1 month since last use of all hormonal contraception, and 4 months since most recent administration of depot medroxyprogesterone, is required prior to enrollment in the study.
• •7. Have regular menstrual cycles (when not on hormonal contraception) with a usual length of 21 to 35 days.
• •8. Stable dose of hydroxyurea and other sickle cell-related medications for the past 6 months
• •9. Access to a device with text-messaging capability
• •10. Must be able to read and understand English
• •11. Willing to comply with study procedures